Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Horizon-HO Study
NCT05147415Phase 2Withdrawn
- Sponsor
- Saniona
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Tesomet in hypothalamic obesity (HO) (5 arms), sponsored by Saniona. Primary endpoint: Percentage Change in Body Weight at 36 weeks. Planned start Nov 2021; status: withdrawn.
02
Drugs
Tesomet
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT05147415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147415.